Revolution Medicines, Inc. RVMDW
Nov 3, 2026, 3:29 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 42.43B
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 8.95K
- Open
- 0.386
- Previous close
- 9.63
- Day's range
- 10.00 – 10.25
- 52-week range
- 10.00 – 10.25
- Beta
- 1.43
- Earnings date
- Nov 4, 2026
2Y 0.00 (0.00%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -711.61M
- Total cash
- 3.94B
- Total debt
- 1.19B
- Return on equity
- -79.09%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -2.35 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -2.04 | -3.06 | -1.02 | -49.81% |
| May 6, 2026 | Mar 31, 2026 | -1.84 | -2.29 | -0.45 | -24.75% |
| Feb 25, 2026 | Dec 31, 2025 | -1.58 | -1.86 | -0.28 | -17.63% |
| Nov 5, 2025 | Sep 30, 2025 | -1.42 | -1.61 | -0.19 | -13.29% |
| Aug 6, 2025 | Jun 30, 2025 | -1.14 | -1.31 | -0.17 | -15.11% |
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Country
- United States
- Website
- revmed.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on RVMDW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| LMR Partners LLP | 45.89% | 5,066,598 | 51.58M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 14.31% | 1,580,345 | 16.09M | Jun 29, 2026 |
| Sculptor Capital LP | 6.43% | 709,670 | 7.22M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.25% | 579,550 | 5.90M | Jun 29, 2026 |
| Caption Management, LLC | 4.69% | 517,685 | 5.27M | Jun 29, 2026 |
| Adage Capital Partners GP L.L.C. | 4.53% | 500,000 | 5.09M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price New Horizons Fund, Inc. | 2.74% | 302,672 | 3.08M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.80% | 198,505 | 2.02M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 0.34% | 37,799 | 384.79K | Jun 29, 2026 |
| T. ROWE PRICE Eqy. SERIES, INC.-T. Rowe Price Health Sciences PORT. | 0.10% | 11,096 | 112.96K | Jun 29, 2026 |
| John Hancock Variable Insurance Trust-Health Sciences Trust | 0.04% | 4,502 | 45.83K | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Equities Trust | 0.01% | 1,529 | 15.56K | Jun 29, 2026 |